Liraglutide

also known as Victoza · Saxenda · LIRA · NNC 90-1170 · NN2211 · - liraglutide (Victoza) · CinnaGen-liraglutide · LIRA 3 mg · +9 more

Peptide targets GCK, GLP1R via activation

Developed for: type 2 diabetes mellitus · obesity disorder · type 1 diabetes mellitus · metabolic disease · diabetes mellitus · polycystic ovary syndrome · morbid obesity · glucose intolerance
+66 more
· NAFLD1 · osteoarthritis · abdominal obesity-metabolic syndrome · atrial fibrillation · cardiovascular disorder · female infertility · gestational diabetes · heart failure · hypertensive disorder · maturity-onset diabetes of the young · metabolic dysfunction-associated steatohepatitis · metabolic dysfunction-associated steatotic liver disease · metabolic syndrome X · obstructive sleep apnea syndrome · osteoarthritis, knee · prediabetes syndrome · psoriasis · acquired hypothalamic obesity · acute leukemia · acute myocardial infarction · Alzheimer disease · atypical endometrial hyperplasia · autonomic nervous system disorder · binge eating disorder · cardiac arrest · cognitive impairment with or without cerebellar ataxia · congestive heart failure · coronary microvascular disorder · delirium · diabetic kidney disease · diabetic neuropathy · diabetic peripheral angiopathy · diabetic polyneuropathy · endometrial endometrioid adenocarcinoma · hyperglycemia · hypoglycemia · intestinal dysmotility syndrome · long COVID-19 · monoclonal gammopathy · multiple sclerosis · myocardial infarction · osteoporosis · peripheral arterial disease · pouchitis · Prader-Willi syndrome · psoriatic arthritis · short bowel syndrome · sleep apnea syndrome · ST-elevation myocardial infarction · substance-related disorder · atherosclerotic cardiovascular disease · bipolar disorder · cardiomyopathy · chronic obstructive pulmonary disease · chronic renal failure syndrome · coronary artery disorder · diastolic heart failure · fatty liver disease · hypogonadism · intermediate coronary syndrome · major depressive disorder · malabsorption syndrome · myocardial ischemia · Parkinson disease · pituitary deficiency · transient ischemic attack
Investigated by: Novo Nordisk A/S · Hvidovre University Hospital · University of Copenhagen · Centre Hospitalier Universitaire Dijon · Henrik Gudbergsen · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
+198 more
· Steno Diabetes Center Copenhagen · Xiangya Hospital of Central South University · National Institutes of Health (NIH) · Rigshospitalet, Denmark · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · University Hospital, Gentofte, Copenhagen · University of Leicester · University of Miami · Aarhus University Hospital · Amsterdam UMC, location VUmc · Anna Cruceta · Beth Israel Deaconess Medical Center · Chen Wei Ren, MD · Chinese PLA General Hospital · Dasman Diabetes Institute · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Imperial College London · Juvenile Diabetes Research Foundation · Mount Sinai Hospital, Canada · National Center for Research Resources (NCRR) · Novartis Pharmaceuticals · Profil Institute for Metabolic Research GmbH · Second Xiangya Hospital of Central South University · Temple University · University Health Network, Toronto · University Hospitals, Leicester · University Medical Centre Ljubljana · University of Aarhus · University of Oxford · University of Virginia · Woman's · Yale University · Academic Medical Center - University of Amsterdam · Affiliated Hospital of Nantong University · Alberta Innovates Health Solutions · Alexandria University · Ali Aminian · American Diabetes Association · American Heart Association · Anders Fink-Jensen, MD, DMSci · Assistance Publique - Hôpitaux de Paris · Association of British Clinical Diabetologists · Avon and Wiltshire Mental Health Partnership NHS Trust · Beni-Suef University · Biolingus · Boehringer Ingelheim · Botkin Hospital · Brigham and Women's Hospital · CHU de Quebec-Universite Laval · Cambridge Weight Plan Limited · Canadian Heads of Academic Radiology-GE Healthcare Development Award · Carla Greenbaum, MD · Catholic University of the Sacred Heart · Cedars-Sinai Medical Center · Centre de Recherche du Centre Hospitalier de l'Université de Montréal · Changzhou No.2 People's Hospital · Children's Hospital Medical Center, Cincinnati · Children's National Research Institute · Chinese University of Hong Kong · Cinnagen · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · David Sanchez Garcia · Diabetes Care Center of Nanjing Military Command · Diabetes Québec · Dynamic Solutions · EU FP7: SAFEGUARD consortium · Eastern Virginia Medical School · Eli Lilly and Company · Emory University · Ethicon, Inc. · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Eva Pharma · Eva Prescott · Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · all 204 on the full record

Regulatory milestones approvals, filings & regulatory actions · 14 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed type 2 diabetes mellitus 3 milestones
Filed	Japan (PMDA)	—	type 2 diabetes mellitus	2008-07-15	“Novo Nordisk har indsendt registreringsansøgning til de japanske myndigheder med henblik på godkendelse af den humane GLP-1-analog liraglutide” novonordisk.com ↗ “submission of a new drug application to the Ministry of Health, Labour and Welfare in Japan for the approval of liraglutide” novonordisk.com ↗
Filed	EU (EMA)	—	type 2 diabetes mellitus	2008-05-23	“as well as a marketing authorisation application to the European Medicines Agency (EMEA) in Europe, for the approval of liraglutide” novonordisk.com ↗
Filed	US (FDA)	—	type 2 diabetes mellitus	2008-05-23	“submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) in the US” novonordisk.com ↗
Approved Indication not stated 4 milestones
Label expansions (4)	US (FDA)	SAXENDA	—	2017-04-26 – 2020-12-04	fda.gov ↗
Label expansions (5)	US (FDA)	VICTOZA	—	2010-12-22 – 2019-06-17	fda.gov ↗
Approved	US (FDA)	VICTOZA	—	2010-01-25	fda.gov ↗
Approved	EU (EMA)	Victoza	—	2009-06-30	europa.eu ↗

Trials 274 · started per year

today

EU approved 2009

US approved 2010

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials · 2 missed
Phase 0	NCT06171152	Jan 2024 → Jun 2027	acute leukemia, long COVID-19, morbid obesity, multiple sclerosis	University of Chicago	Suspended	No outcome recorded
Phase 0	NCT06217848	Nov 2022 → Feb 2024	acquired hypothalamic obesity, craniopharyngioma, panhypopituitarism	Seoul National University Hospital	Unknown	No outcome recorded
Phase 0	NCT03632759	Aug 2018 → Nov 2021	type 1 diabetes mellitus	Carla Greenbaum, MD	Completed	Missed primary
Phase 0	NCT03500484	Jun 2018 → Jun 2020	obesity disorder	Yale University	Terminated	No outcome recorded Stop: Business
Phase 0	NCT01856790	Feb 2013 → Nov 2015	type 1 diabetes mellitus	Jennifer Sherr	Completed	Missed primary
Phase 151 trials · 7 met primary · 3 missed
Phase 1	NCT07225816	Nov 2025 → Jun 2026 overdue	obesity disorder	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 1	NCT06439056	May 2024 → Jul 2025	type 2 diabetes mellitus	Nanexa AB	Completed	No outcome recorded
Phase 1	NCT06449703	May → Jun 2024	—	Tonghua Dongbao Pharmaceutical Co.,Ltd	Unknown	No outcome recorded
Phase 1	NCT05225974	Jul 2021	—	The Affiliated Hospital of Qingdao University	Completed	No outcome recorded
Phase 1	NCT04903509	Jun 2021 → Aug 2022	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT05294536	Jun → Jul 2020	type 2 diabetes mellitus	Sunshine Lake Pharma Co., Ltd.	Completed	Met primary
Phase 1	NCT03292185	Sep 2017 → Jan 2018	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT03041792	Feb 2017 → Jan 2018	obesity disorder	Pfizer	Completed	Met primary
Phase 1	NCT02870231	Aug 2016 → Sep 2017	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT02717858	Mar 2016 → Feb 2017	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Missed primary
Phase 1	NCT02696148	Mar 2016 → Apr 2017	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT02231658	Jul 2015 → Jul 2018	diabetes mellitus	Profil Institute for Metabolic Research GmbH	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02650206	Jan 2015 → Sep 2019	type 2 diabetes mellitus	Stanford University	Completed	No outcome recorded
Phase 1	NCT02235961	Sep 2014 → Jul 2016	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT02109315	May 2014 → May 2015	type 1 diabetes mellitus	Anna Cruceta	Withdrawn	No outcome recorded
Phase 1	NCT02059564	Dec 2013 → Oct 2014	diabetes mellitus	Hanmi Pharmaceutical Company Limited	Unknown	No outcome recorded
Phase 1	NCT01789086	Feb 2013 → May 2014	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01550653	May 2012 → Dec 2013	—	University of Luebeck	Completed	No outcome recorded
Phase 1	NCT01536665	Feb → Aug 2012	type 1 diabetes mellitus	Novo Nordisk A/S	Completed	Missed primary
Phase 1	NCT01473953	Oct 2011 → Mar 2012	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01373450	Jun → Jul 2011	type 2 diabetes mellitus	Merck Sharp & Dohme LLC	Completed	Met primary
Phase 1	NCT00943501	Nov 2009 → Sep 2011	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT00993304	Oct 2009 → Dec 2010	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 1	NCT00978393	Sep 2009 → Jun 2011	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 1	NCT00983021	Sep → Dec 2009	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT00873223	Mar → Sep 2009	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT00761540	Oct → Dec 2008	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01513525	Feb → May 2007	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01517568	Nov → Dec 2006	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01508858	Nov 2006 → Apr 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01517555	Oct 2006 → May 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 1	NCT01516255	Jul → Nov 2006	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 1	NCT01518166	May 2006 → Apr 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Missed primary
Phase 1	NCT01515579	Apr → Jun 2006	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01507389	Mar → Jun 2006	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01515592	Jan → Apr 2006	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01511692	Nov 2005 → Sep 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01508806	Aug 2005 → Mar 2006	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01514487	Jan → Mar 2005	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01508897	May → Jun 2004	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01507337	Apr → Jun 2004	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01615978	Dec 2003 → Mar 2004	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01620476	Sep 2003 → Mar 2004	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01620463	Dec 2002 → Mar 2003	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01511159	Oct → Dec 2001	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01509742	Apr → Nov 2001	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01511185	Feb → Oct 2001	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01507311	Sep → Dec 1999	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01507285	Aug → Nov 1999	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01507272	Mar → Dec 1999	diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT00013910	—	type 2 diabetes mellitus	National Center for Research Resources (NCRR)	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT05268237	Apr 2023 → Dec 2025 overdue	type 2 diabetes mellitus	Biolingus	Recruiting	No outcome recorded
Phase 1/2	NCT04199728	Oct 2021 → Sep 2023	substance-related disorder	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 1/2	NCT03182426	Aug 2017 → Jul 2024	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 1/2	NCT02960659	May 2017 → May 2022	type 2 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 1/2	NCT03011021	Jan 2017 → Jun 2025	type 1 diabetes mellitus	Second Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 1/2	NCT01954147	Oct 2013 → Oct 2014	type 2 diabetes mellitus	Diabetes Care Center of Nanjing Military Command	Unknown	No outcome recorded
Phase 1/2	NCT01832532	Apr 2013 → Dec 2015	sleep apnea syndrome	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 233 trials · 8 met primary · 1 missed
Phase 2	NCT07107334	Apr 2026 → Nov 2028 expected	endometrial endometrioid adenocarcinoma	University of Florida	Recruiting	No outcome recorded
Phase 2	NCT07029009	May 2025 → Aug 2026 overdue	maturity-onset diabetes of the young	Mansa	Recruiting	No outcome recorded
Phase 2	NCT04763564	Mar 2022 → Oct 2023	intestinal dysmotility syndrome, pouchitis	University of North Carolina, Chapel Hill	Terminated	Met primary
Phase 2	NCT04883346	Jun 2021 → Mar 2024	obesity disorder, postgastrectomy syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 2	NCT04529278	Jan 2021 → Jan 2023	obesity disorder, type 2 diabetes mellitus	Fondation Hôpital Saint-Joseph	Unknown	No outcome recorded
Phase 2	NCT04535960	Jan 2019 → Oct 2023	type 2 diabetes mellitus	University Health Network, Toronto	Unknown	No outcome recorded
Phase 2	NCT03712098	Nov 2018 → May 2022	—	Rebecca Ashare	Completed	No outcome recorded
Phase 2	NCT04839237	Dec 2017 → Dec 2020	obesity disorder	Xiangya Hospital of Central South University	Withdrawn	No outcome recorded
Phase 2	NCT03523273	Nov 2017 → Aug 2021	obesity disorder	Michael Camilleri, MD	Completed	No outcome recorded
Phase 2	NCT03371862	Oct 2017 → Aug 2020	short bowel syndrome	Imperial College London	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT03426085	May 2016 → Apr 2020	autonomic nervous system disorder, diabetic neuropathy, sweat gland disorder	Eastern Virginia Medical School	Unknown	No outcome recorded
Phase 2	NCT02443155	Nov 2015 → Aug 2018	type 1 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 2	NCT02472717	May 2015 → Oct 2016	glucose intolerance, psoriasis, psoriatic arthritis, type 2 diabetes mellitus	University Health Network, Toronto	Withdrawn	No outcome recorded
Phase 2	NCT02082496	Jun 2014 → Apr 2016	obesity disorder	University of Copenhagen	Completed	No outcome recorded
Phase 2	NCT01843075	Jan 2014 → Dec 2019	Alzheimer disease	Imperial College London	Unknown	Missed primary
Phase 2	NCT01845259	Apr 2013 → Mar 2016	glucose intolerance	Psychiatric Centre Rigshospitalet	Unknown	Met primary
Phase 2	NCT02113332	Jan 2013 → Aug 2014	type 2 diabetes mellitus	Vastra Gotaland Region	Completed	No outcome recorded
Phase 2	NCT01658501	Jul 2012 → Jul 2013	type 2 diabetes mellitus	PhaseBio Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 2	NCT01206101	Mar 2012 → Jun 2013	type 1 diabetes mellitus	Novo Nordisk A/S	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01782261	Feb 2012 → Feb 2015	type 1 diabetes mellitus	Medical University of Graz	Completed	No outcome recorded
Phase 2	NCT01425580	Jan 2012 → Aug 2016	congestive heart failure, type 2 diabetes mellitus	Thomas Nystrom	Completed	No outcome recorded
Phase 2	NCT01516476	Nov 2011 → Jan 2012	type 2 diabetes mellitus	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 2	NCT01399645	May 2011 → Jun 2014	NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 2	NCT01237119	Aug 2010 → Jul 2014	metabolic dysfunction-associated steatohepatitis	University of Birmingham	Completed	Met primary
Phase 2	NCT00696657	Jun 2008 → Feb 2009	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 2	NCT00422058	Jan → Sep 2007	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 2	NCT00154401	Jan → Oct 2005	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT00154414	Jan 2005 → May 2006	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT01511172	Aug → Dec 2002	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 2	NCT01508949	Jun 2001 → Mar 2002	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT01508923	May 2001 → Feb 2002	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT01511198	Feb → Oct 2001	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT01509755	Oct 2000 → Oct 2001	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary

Phase 2/35 trials · 1 met primary
Phase 2/3	NCT04683237	Mar 2021 → Nov 2025	atypical endometrial hyperplasia, infertility disorder, obesity disorder	Xiaojun Chen	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2/3	NCT02584582	Jul → Nov 2015	type 1 diabetes mellitus	Hvidovre University Hospital	Unknown	No outcome recorded
Phase 2/3	NCT02351232	Feb 2015 → Oct 2016	type 1 diabetes mellitus	Hvidovre University Hospital	Completed	Met primary
Phase 2/3	NCT01610934	Aug 2012 → Aug 2013	maturity-onset diabetes of the young	University Hospital, Gentofte, Copenhagen	Completed	No outcome recorded
Phase 2/3	NCT00993720	Oct 2009 → Oct 2010	type 1 diabetes mellitus	Hvidovre University Hospital	Completed	No outcome recorded
Phase 358 trials · 39 met primary · 2 missed
Phase 3	NCT06361238	Nov 2024 → Mar 2027 expected	delirium	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Recruiting	No outcome recorded
Phase 3	NCT05965908	Jan 2024 → Mar 2025	polycystic ovary syndrome	Beni-Suef University	Completed	No outcome recorded
Phase 3	NCT05952882	Nov 2023 → Dec 2025	female infertility, obesity disorder, polycystic ovary syndrome	My Duc Hospital	Unknown	No outcome recorded
Phase 3	NCT05767255	Dec 2022 → Aug 2023	type 2 diabetes mellitus	Hospital Universitario San Ignacio	Unknown	Met primary
Phase 3	NCT05467514	Jul 2022 → Feb 2023	type 1 diabetes mellitus	David Sanchez Garcia	Completed	No outcome recorded
Phase 3	NCT04775082	Mar 2021 → Aug 2023 overdue	obesity disorder	Novo Nordisk A/S	Active not recruiting	Met primary
Phase 3	NCT04605861	Aug 2020 → Dec 2022	obesity disorder	Shanghai Zhongshan Hospital	Completed	No outcome recorded
Phase 3	NCT04525300	May 2020 → Jun 2022	obesity disorder	Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 3	NCT04487743	May 2020 → Jun 2022	obesity disorder	Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 3	NCT03421119	Jun → Dec 2019	type 2 diabetes mellitus	Cinnagen	Unknown	Met primary
Phase 3	NCT03480022	Sep 2018 → Feb 2021	obesity disorder, polycystic ovary syndrome, prediabetes syndrome	Woman's	Completed	Met primary
Phase 3	NCT03671733	Sep 2018 → Sep 2022	obesity disorder	Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 3	NCT03672812	Sep 2018 → Dec 2019	cardiac arrest	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 3	NCT03374956	Dec 2017 → May 2022	obesity disorder	Mayo Clinic	Completed	Met primary
Phase 3	NCT03172494	May 2017 → Jun 2019	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02964247	Mar 2017 → May 2018	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02963922	Feb 2017 → Sep 2018	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02963935	Feb 2017 → May 2018	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02889510	Oct 2016 → Nov 2019	type 2 diabetes mellitus	Lecube, Albert, M.D.	Completed	No outcome recorded
Phase 3	NCT02918279	Sep 2016 → Feb 2019	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT04325581	Aug 2016 → Dec 2018	—	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 3	NCT02718950	Jun 2016 → Mar 2017	obesity disorder, type 2 diabetes mellitus	University of Campinas, Brazil	Unknown	No outcome recorded
Phase 3	NCT02501161	Jan 2016 → Oct 2018	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02607306	Nov 2015 → Dec 2017	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02527200	Nov 2015 → Nov 2020	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Missed primary
Phase 3	NCT02505334	Jul 2015 → May 2017	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02098395	May 2014 → Apr 2015	type 1 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02043054	Dec 2013 → Sep 2017	cardiovascular disorder, type 2 diabetes mellitus	University of Leicester	Completed	No outcome recorded
Phase 3	NCT01836523	Nov 2013 → Jun 2015	type 1 diabetes mellitus	Novo Nordisk A/S	Completed	Mixed
Phase 3	NCT01541215	Nov 2012 → Nov 2017	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01617434	Sep 2012 → Oct 2013	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01676116	Aug 2012 → Mar 2014	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01620489	Jun 2012 → Aug 2013	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01557166	Jun 2012 → Jun 2013	metabolic disease, obesity disorder, obstructive sleep apnea syndrome	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02516657	May 2012 → Aug 2022	type 1 diabetes mellitus	University at Buffalo	Completed	No outcome recorded
Phase 3	NCT01572740	Apr → Nov 2012	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01512108	Jan 2012 → Apr 2013	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT01392573	Nov 2011 → Oct 2012	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01388361	Sep 2011 → Jul 2012	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01234649	Aug 2011 → Apr 2019	gestational diabetes, glucose intolerance, metabolic syndrome X, type 2 diabetes mellitus	Woman's	Completed	Met primary
Phase 3	NCT01272232	Jun 2011 → Jan 2013	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01272219	Jun 2011 → Mar 2013	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01336023	May 2011 → May 2012	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01270789	Jan 2011 → Dec 2013	type 2 diabetes mellitus	Mount Sinai Hospital, Canada	Completed	Met primary
Phase 3	NCT01179048	Aug 2010 → Dec 2015	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00856986	Mar 2009 → Apr 2010	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00781937	Oct 2008 → Sep 2010	metabolic disease, obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00700817	Jun 2008 → Jun 2009	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00620282	Feb 2008 → May 2010	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Missed primary
Phase 3	NCT00614120	Jan 2008 → Feb 2009	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00518882	Aug 2007 → Apr 2008	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00393718	Nov 2006 → Nov 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00395746	Oct 2006 → Oct 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00318461	May 2006 → May 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00331851	May 2006 → Apr 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00318422	May 2006 → May 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00333151	May 2006 → Aug 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00294723	Feb 2006 → Nov 2008	type 2 diabetes mellitus	Novo Nordisk A/S	Terminated	Met primary

Phase 486 trials · 13 met primary · 6 missed
Phase 4	NCT07027969	Nov 2026 → Dec 2029 expected	atrial fibrillation, obesity disorder	Ali Aminian	Not yet recruiting	No outcome recorded
Phase 4	NCT06742710	May 2025 → May 2029 expected	female infertility, obesity disorder, polycystic ovary syndrome	Peking University Third Hospital	Recruiting	No outcome recorded
Phase 4	NCT06865365	May 2025 → Feb 2027 expected	—	Medical University of Vienna	Not yet recruiting	No outcome recorded
Phase 4	NCT07244003	Mar 2025 → Dec 2027 expected	type 2 diabetes mellitus	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 4	NCT06438146	May 2024 → May 2025	HIV infectious disease, obesity disorder	Brigham and Women's Hospital	Unknown	No outcome recorded
Phase 4	NCT07590219	Mar 2024 → Apr 2027 expected	morbid obesity	University of Sao Paulo General Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT06501326	Nov 2023 → Oct 2024	NAFLD1, obesity disorder	Affiliated Hospital of Nantong University	Unknown	No outcome recorded
Phase 4	NCT07374445	Sep 2023 → Jun 2025	obesity disorder	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Completed	No outcome recorded
Phase 4	NCT06201819	Dec 2022 → Mar 2023	morbid obesity	Hospital Civil Juan I. Menchaca	Completed	No outcome recorded
Phase 4	NCT04781998	Jul 2021 → Jul 2022	mental disorder, metabolic disease	Anders Fink-Jensen, MD, DMSci	Completed	No outcome recorded
Phase 4	NCT04881110	Feb 2021 → Dec 2022	peripheral arterial disease, type 2 diabetes mellitus	University of Campania Luigi Vanvitelli	Completed	Met primary
Phase 4	NCT04575844	Nov 2020 → Apr 2027 expected	metabolic syndrome X	University of Virginia	Recruiting	No outcome recorded
Phase 4	NCT04531176	Sep 2020 → Aug 2022	obesity disorder, type 2 diabetes mellitus	The Cleveland Clinic	Terminated	Mixed
Phase 4	NCT02920190	Sep 2020 → Sep 2021	monoclonal gammopathy, obesity disorder	University of Miami	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT04146155	May 2020 → Dec 2021	diabetic peripheral angiopathy, type 2 diabetes mellitus	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT04008290	Apr 2020 → Apr 2021	obesity disorder	Universitaire Ziekenhuizen KU Leuven	Unknown	No outcome recorded
Phase 4	NCT04135287	Mar 2020 → Mar 2023	type 2 diabetes mellitus	Dasman Diabetes Institute	Unknown	No outcome recorded
Phase 4	NCT02198209	Dec 2019 → Jul 2020	type 2 diabetes mellitus	Cedars-Sinai Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT04027023	Oct 2019 → Apr 2021	type 2 diabetes mellitus	Sciema UG	Unknown	No outcome recorded
Phase 4	NCT03856632	Mar 2019 → Dec 2026 expected	atrial fibrillation	University of Miami	Active not recruiting	No outcome recorded
Phase 4	NCT03883412	Feb 2019 → Jun 2025	type 2 diabetes mellitus	University of Virginia	Unknown	No outcome recorded
Phase 4	NCT03087032	Jan 2019 → Jan 2025 overdue	hyperglycemia, type 2 diabetes mellitus	The First Affiliated Hospital of Xiamen University	Recruiting	No outcome recorded
Phase 4	NCT03799198	Jan 2019 → May 2020	obesity disorder	Novo Nordisk A/S	Completed	Met primary
Phase 4	NCT03341429	Aug 2018 → Nov 2019	obesity disorder	University College, London	Completed	Met primary
Phase 4	NCT03347890	Mar 2018 → Mar 2020	obesity disorder	Zoltan Pataky	Completed	No outcome recorded
Phase 4	NCT03036800	Nov 2017 → Feb 2021	diabetes mellitus, obesity disorder	University of Leicester	Completed	Met primary
Phase 4	NCT03449654	Oct 2017 → Aug 2019	type 2 diabetes mellitus	Steno Diabetes Center Copenhagen	Completed	Missed primary
Phase 4	NCT03804411	Aug 2017 → Mar 2020	type 2 diabetes mellitus	Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health	Unknown	No outcome recorded
Phase 4	NCT03151005	Jul 2017 → Apr 2021	obesity disorder, polycystic ovary syndrome	Xinqiao Hospital of Chongqing	Completed	No outcome recorded
Phase 4	NCT03048578	May 2017 → Mar 2021	obesity disorder	NYU Langone Health	Completed	No outcome recorded
Phase 4	NCT03101930	May 2017 → Jun 2021	obesity disorder, prediabetes syndrome	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT03038620	Jan 2017 → Oct 2020	cardiovascular disorder, obesity disorder	University of Texas Southwestern Medical Center	Completed	Met primary
Phase 4	NCT03011008	Jan 2017 → Dec 2020	type 1 diabetes mellitus	Second Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 4	NCT02928679	Nov 2016 → Feb 2019	obesity disorder, osteoarthritis, knee	Henrik Gudbergsen	Completed	No outcome recorded
Phase 4	NCT02905864	Nov 2016 → Feb 2019	obesity disorder, osteoarthritis	Henrik Gudbergsen	Completed	No outcome recorded
Phase 4	NCT02928614	Nov 2016 → Feb 2019	obesity disorder, osteoarthritis	Henrik Gudbergsen	Completed	No outcome recorded
Phase 4	NCT02944500	Nov 2016 → Jun 2027 expected	obesity disorder	Beth Israel Deaconess Medical Center	Active not recruiting	No outcome recorded
Phase 4	NCT02910570	Nov 2016 → Feb 2019	osteoarthritis, knee	Parker Research Institute	Completed	No outcome recorded
Phase 4	NCT02931383	Nov 2016 → Feb 2019	obesity disorder, osteoarthritis	Henrik Gudbergsen	Completed	No outcome recorded
Phase 4	NCT04122716	Sep 2016 → Nov 2019	obesity disorder	Signe Torekov	Unknown	Met primary
Phase 4	NCT02743598	Sep 2016 → Jun 2018	HIV infectious disease, abdominal obesity-metabolic syndrome, obesity disorder, type 2 diabetes mellitus	Temple University	Terminated	No outcome recorded Stop: Business
Phase 4	NCT02535299	Jun 2016 → Dec 2018	—	Third Military Medical University	Unknown	No outcome recorded
Phase 4	NCT02686177	May 2016 → Aug 2017	type 2 diabetes mellitus	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT02730377	Mar 2016 → Aug 2019	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 4	NCT02832999	Jan → Sep 2016	type 2 diabetes mellitus	Yaounde Central Hospital	Completed	No outcome recorded
Phase 4	NCT02602600	Nov 2015 → Apr 2017	coronary microvascular disorder	Eva Prescott	Completed	Missed primary
Phase 4	NCT02527993	Oct 2015 → Apr 2017	hypoglycemia, obesity disorder	Zealand University Hospital	Completed	No outcome recorded
Phase 4	NCT02473809	Aug 2015 → Oct 2017	osteoporosis	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT02909933	Jul → Oct 2015	obesity disorder, polycystic ovary syndrome	University Medical Centre Ljubljana	Completed	Met primary
Phase 4	NCT02503943	May 2015 → Sep 2016	hypertensive disorder, obesity disorder, type 2 diabetes mellitus	Third Affiliated Hospital of Third Military Medical University	Unknown	No outcome recorded
Phase 4	NCT02545738	Apr 2015 → May 2016	diabetic kidney disease	Steno Diabetes Center Copenhagen	Completed	Met primary
Phase 4	NCT02765399	Feb 2015 → Feb 2019	type 2 diabetes mellitus	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT02501850	Oct 2014 → Jul 2015	type 2 diabetes mellitus	Hospital Universitari Vall d'Hebron Research Institute	Unknown	No outcome recorded
Phase 4	NCT02089256	Jun 2014 → Mar 2015	—	University of Tartu	Completed	No outcome recorded
Phase 4	NCT02060383	May 2014 → Feb 2018	Cushing disease due to pituitary adenoma, acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02344186	May 2014 → Dec 2022	type 2 diabetes mellitus	Temple University	Unknown	No outcome recorded
Phase 4	NCT02616003	Apr 2014 → Jan 2018	morbid obesity	Sana Klinikum Offenbach	Completed	No outcome recorded
Phase 4	NCT01919489	Mar 2014 → Aug 2020	type 2 diabetes mellitus	Emory University	Completed	No outcome recorded
Phase 4	NCT02014740	Mar 2014 → Mar 2017	obesity disorder, type 2 diabetes mellitus	University of Miami	Completed	No outcome recorded
Phase 4	NCT02674893	Feb 2014 → Aug 2016	obesity disorder, type 2 diabetes mellitus	Centre Hospitalier Universitaire Dijon	Terminated	No outcome recorded
Phase 4	NCT02072096	Feb 2014 → Oct 2015	type 2 diabetes mellitus	Eli Lilly and Company	Terminated	Missed primary
Phase 4	NCT01917656	Jan → Sep 2014	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Missed primary
Phase 4	NCT01907854	Dec 2013 → Jun 2015	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 4	NCT02008682	Dec 2013 → Nov 2014	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 4	NCT01973231	Oct 2013 → Nov 2014	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	Met primary
Phase 4	NCT02055014	Jul 2013 → Mar 2017	obesity disorder, type 2 diabetes mellitus	Sandwell & West Birmingham Hospitals NHS Trust	Unknown	No outcome recorded
Phase 4	NCT01787916	Apr 2013 → Apr 2015	type 1 diabetes mellitus	CHU de Quebec-Universite Laval	Completed	No outcome recorded
Phase 4	NCT01744236	Apr 2013 → Aug 2015	type 2 diabetes mellitus	Amsterdam UMC, location VUmc	Completed	Missed primary
Phase 4	NCT02403284	Mar 2013 → Apr 2021	—	Phoenix VA Health Care System	Completed	No outcome recorded
Phase 4	NCT01785043	Mar 2013 → Mar 2014	type 2 diabetes mellitus	Anna Cruceta	Completed	No outcome recorded
Phase 4	NCT01755572	Jan 2013 → Jan 2014	hypertensive disorder, type 2 diabetes mellitus	Mount Sinai Hospital, Canada	Completed	No outcome recorded
Phase 4	NCT01664676	Dec 2012 → Feb 2014	type 2 diabetes mellitus	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT01739049	Nov 2012 → Oct 2013	binge eating disorder	Universiti Kebangsaan Malaysia Medical Centre	Completed	No outcome recorded
Phase 4	NCT01499108	Aug 2012 → Jul 2013	type 2 diabetes mellitus	Peter Rossing	Completed	No outcome recorded
Phase 4	NCT02721888	Jul 2012 → Oct 2019	type 2 diabetes mellitus	Centre Hospitalier Universitaire Dijon	Terminated	No outcome recorded
Phase 4	NCT01795248	Jul 2012 → Sep 2019	gestational diabetes	Tina Vilsboll	Completed	No outcome recorded
Phase 4	NCT01612468	Jun 2012 → Feb 2015	obesity disorder, type 1 diabetes mellitus	Steno Diabetes Center Copenhagen	Completed	Missed primary
Phase 4	NCT01592279	Jun 2012 → Jun 2014	—	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 4	NCT01593137	May 2012 → Dec 2013	type 2 diabetes mellitus	Fundación Fernández-Cruz	Withdrawn	No outcome recorded
Phase 4	NCT01562678	Mar 2012 → May 2014	type 2 diabetes mellitus	Beth Israel Deaconess Medical Center	Completed	Met primary
Phase 4	NCT01542242	Feb 2012 → Mar 2013	Prader-Willi syndrome, type 2 diabetes mellitus	Vancouver General Hospital	Terminated	No outcome recorded
Phase 4	NCT01518101	Jan → Oct 2012	type 2 diabetes mellitus	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01654120	Dec 2011 → Nov 2013	type 2 diabetes mellitus	Mountain Diabetes and Endocrine Center	Completed	No outcome recorded
Phase 4	NCT01899430	Nov 2011 → Oct 2012	obesity disorder, polycystic ovary syndrome	University Medical Centre Ljubljana	Completed	No outcome recorded
Phase 4	NCT02292290	Apr 2011 → Dec 2012	type 2 diabetes mellitus	University of Leicester	Completed	No outcome recorded
Phase 4	NCT01208012	Apr → Nov 2010	type 2 diabetes mellitus	ikfe-CRO GmbH	Completed	No outcome recorded

Phase not applicable29 trials · 4 met primary · 1 missed
—	NCT06818292	Oct → Dec 2024	—	Nils Opel	Completed	No outcome recorded
—	NCT05390307	Apr 2023 → Jan 2024	type 1 diabetes mellitus	Dasman Diabetes Institute	Completed	No outcome recorded
—	NCT05779644	Feb 2023 → Feb 2025	abdominal obesity-metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus	RenJi Hospital	Unknown	No outcome recorded
—	NCT05313529	Oct 2022 → Dec 2025 overdue	cognitive impairment with or without cerebellar ataxia, type 2 diabetes mellitus	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Active not recruiting	No outcome recorded
—	NCT05285397	Mar → Sep 2022	morbid obesity	General Committee of Teaching Hospitals and Institutes, Egypt	Unknown	No outcome recorded
—	NCT07539584	Mar 2022 → Apr 2024	metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus	Moscow Regional Research and Clinical Institute (MONIKI)	Completed	No outcome recorded
—	NCT05041673	Feb → Sep 2021	NAFLD1, type 2 diabetes mellitus	Alexandria University	Unknown	No outcome recorded
—	NCT04643301	Dec 2020 → Dec 2021	morbid obesity	Zuyderland Medical Center	Withdrawn	No outcome recorded
—	NCT04186494	Dec 2019 → Dec 2021	obstructive sleep apnea syndrome	St Vincent's University Hospital, Ireland	Completed	No outcome recorded
—	NCT04137328	Nov 2019 → Nov 2022	diabetic polyneuropathy	Fudan University	Unknown	No outcome recorded
—	NCT03795701	Jan 2019 → May 2022	obesity disorder	Texas Tech University	Completed	No outcome recorded
—	NCT04190160	Nov 2018 → Nov 2019	type 2 diabetes mellitus	Stefano Rizza	Completed	No outcome recorded
—	NCT03498001	Apr 2018 → Jun 2023	type 2 diabetes mellitus	Centre Hospitalier Universitaire Dijon	Completed	No outcome recorded
—	NCT03520062	Aug 2017 → Apr 2019	obesity disorder	Nicolai Jacob Wewer Albrechtsen	Completed	No outcome recorded
—	NCT02783196	Jul → Dec 2016	type 2 diabetes mellitus	Tel Aviv University	Unknown	No outcome recorded
—	NCT02650596	Jan 2016 → Feb 2018	heart failure	Shi Yang	Unknown	Met primary
—	NCT03534310	Nov 2015 → Jan 2017	obesity disorder	Catholic University of the Sacred Heart	Completed	No outcome recorded
—	NCT02577848	Oct 2015 → Oct 2016	myocardial infarction	Chinese PLA General Hospital	Unknown	No outcome recorded
—	NCT02490176	Jul 2015 → Jul 2016	heart failure	Chinese PLA General Hospital	Unknown	No outcome recorded
—	NCT02507128	Jul 2015 → Jul 2016	ST-elevation myocardial infarction	Chen Wei Ren, MD	Unknown	No outcome recorded
—	NCT02036372	Jan 2014 → Jan 2017	type 2 diabetes mellitus	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
—	NCT02001363	Nov 2013 → Mar 2016	acute myocardial infarction	Chen Wei Ren, MD	Unknown	Met primary
—	NCT01974544	May 2013 → Dec 2015	type 2 diabetes mellitus	Pontificia Universidad Catolica de Chile	Unknown	No outcome recorded
—	NCT01392898	Feb 2012 → May 2014	type 2 diabetes mellitus	Radboud University Medical Center	Unknown	Met primary
—	NCT01687582	Jan → Dec 2012	psoriasis, type 2 diabetes mellitus	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Completed	No outcome recorded
—	NCT01232946	Jan 2012 → Sep 2017	type 2 diabetes mellitus	Indiana University	Completed	Missed primary
—	NCT01363609	Oct 2011 → Jan 2015	obesity disorder, type 2 diabetes mellitus	Amsterdam UMC, location VUmc	Completed	Met primary
—	NCT01575301	Mar 2011 → Jul 2015	diabetes mellitus	University of Dundee	Completed	No outcome recorded
—	NCT01599338	Jan 2011	obesity disorder, type 2 diabetes mellitus	Centre Hospitalier Universitaire Dijon	Completed	No outcome recorded

Comparator or background therapy136 trials
Phase 1	NCT05794581 Comparator	Mar 2023 → Mar 2024	type 1 diabetes mellitus	Carmot Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT05444569 Background	Aug 2022 → Feb 2023	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT04311411 Comparator	Aug 2020 → Dec 2022	obesity disorder	Eli Lilly and Company	Completed	Met primary
Phase 1	NCT03757130 Background	Nov 2018 → Dec 2019	obesity disorder	Amgen	Completed	No outcome recorded
Phase 1	NCT03115099 Comparator	May 2017 → Apr 2018	type 2 diabetes mellitus	Eli Lilly and Company	Completed	No outcome recorded
Show all 136 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 117

Date	Issuer	Release
2026-07-13	4Moving Biotech	Results Discover new insights into the effects of liraglutide in advanced 3D human osteoarthritic chondrocyte models from a study co-authored by Pr. Francis Berenbaum, CMO at 4Moving Biotech 4movingbiotech.com ↗ The study explores the effects of liraglutide in advanced 3D human osteoarthritic chondrocyte models, providing new insights into its ability to modulate inflammatory responses while supporting cartilage matrix homeostasis and anabolic activity.
2026-06-17	Lexaria Bioscience Corp.	Results GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand lexariabioscience.com ↗ The following table summarizes the dramatic improvements in GI AEs that Lexaria has realized when testing three (semaglutide, tirzepatide, and liraglutide) of the major GLP-1 drugs on the market today with its DehydraTECH™ technology in an oral format:
2026-02-05	Lexaria Bioscience Corp.	Results Lexaria Announces Positive Final Results From Human Pilot Study #5 lexariabioscience.com ↗
2025-11-06	4Moving Biotech	Results Professor Francis Berenbaum highlighted new advances in osteoarthritis research at ACR Convergence 2025 4movingbiotech.com ↗ He also presented the oral abstract “Intra-articular liraglutide halts osteoarthritis progression, surpassing dexamethasone in synovial and cartilage protection,” showcasing compelling preclinical results supporting the potential of GLP-1 receptor agonists to target both inflammation and cartilage degradation.
2025-08-28	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss tevapharm.com ↗ Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection).
2025-08-28	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss tevapharm.com ↗ Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection).
2025-07-24	Lupin Limited	Regulatory Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products lupin.com ↗
2025-06-24	Nanexa AB	Results Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago nanexa.com ↗ A 30 mg dose of NEX-22 shows exposure for up to 36 days without significant gastrointestinal side effects.
2025-06-11	Lexaria Bioscience Corp.	Results Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule lexariabioscience.com ↗ With those AEs removed from the analysis, oral DehydraTECH-liraglutide offered a 22.7% reduction in AEs as compared to the injected Saxenda®.
2025-06-03	Nanexa AB	Results Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure nanexa.com ↗ In the recently completed Phase I study, NEX-22 demonstrated a dose-proportional increase in exposure and a controlled release of the drug over one month following a single subcutaneous injection.
2025-05-23	Nanexa AB	Results All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study nanexa.com ↗ The results show increased exposure in line with the dose escalation and further demonstrate a controlled and prolonged release of liraglutide, which supports a one-month depot of liraglutide.
2025-04-07	Nanexa AB	Results Continued Good Tolerability of NEX-22 at 30 mg Dose of Liraglutide in the NEX-22 Study nanexa.com ↗ After an injection of NEX-22 with 30 mg liraglutide released over a month, no nausea, vomiting or diarrhea was observed in the three patients dosed.
2025-04-03	Meitheal Pharmaceuticals, Inc.	Regulatory Meitheal Pharmaceuticals Announces Approval and Launch of Liraglutide Injection in the United States meithealpharma.com ↗ Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has received U.S. Food and Drug Administration (FDA) approval for and launched liraglutide injection (18mg/3mL), its generic equivalent for Victoza ®2 in the U.S.
2025-01-28	Nanexa AB	Regulatory Nanexa expands Phase I study with NEX-22 with an additional dose group nanexa.com ↗ The study will now continue to include patients after receiving regulatory approval to add a dose group for the administration of 30 mg liraglutide.
2024-12-26	Roxane Laboratories	Regulatory Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US hikma.com ↗ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has received FDA approval for and launched its generic version of Victoza®, Liraglutide Injection, in a 6 mg/mL dosage in the US.
2024-11-22	Nanexa AB	Results All Primary and Secondary endpoints met in Nanexa’s Phase I study of the one-month GLP-1 depot NEX-22 nanexa.com ↗ The study met all primary and secondary endpoints.
2024-10-24	Lexaria Bioscience Corp.	Results Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗ DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups
2024-10-22	Lexaria Bioscience Corp.	Results Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗ Actual weight decreases or slower rates of weight gain have since been achieved in the 12 weeks of dosing in all Study groups receiving DehydraTECH drug therapies.
2024-09-17	Nanexa AB	Results Nanexa starts the final dose group in the Phase 1 study of NEX-22 for treatment of Type 2 Diabetes nanexa.com ↗ Preliminary data from the first two dose groups shows that Nanexa’s PharmaShell® technology enables a controlled and prolonged release of liraglutide, with an increase in plasma concentration proportional to dose.
2024-08-22	Lexaria Bioscience Corp.	Results Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗ DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide
2024-08-21	Lexaria Bioscience Corp.	Results Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study lexariabioscience.com ↗ DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) were the top performers in the Study at day 56, with blood sugar level reductions of 2.50%, 1.90% and 1.53% respectively.
2024-08-01	Nanexa AB	Results Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan nanexa.com ↗ We are pleased to have the first clinical results for NEX-22 in patients with type 2 diabetes clearly confirming a prolonged release with an extended pharmacokinetic profile while the safety profile is observed with only mild injection site reactions,
2024-07-17	Lexaria Bioscience Corp.	Results Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study lexariabioscience.com ↗
2024-06-10	4Moving Biotech	Results 4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients 4movingbiotech.com ↗ The trial reached its primary objective, confirming that intra-articular liraglutide (4P004) was safe and well tolerated.
2024-05-15	Nanexa AB	Regulatory Nanexa receives approval for NEX-22 clinical study nanexa.com ↗ Nanexa AB today announces that the European Medicines Agency has approved the company's clinical trial application for the Phase I study with NEX-22.
2024-04-16	Nanexa AB	Regulatory Approval of clinical trial application for NEX-22 study delayed nanexa.com ↗ The company sees no difficulty in answering these, but the application will not be approved in April with the current timeline.
2023-08-23	Nanexa AB	Results Nanexa publishes interim report for January – June 2023 nanexa.com ↗ Nanexa AB announced that a preclinical study of NEX-22 in minipigs confirms a long release profile of liraglutide, which was previously seen in rats.
2023-08-22	Nanexa AB	Results Nanexa confirms continued positive results from a new preclinical study of NEX-22 nanexa.com ↗ Nanexa AB today announced that a preclinical study of NEX-22 in minipigs confirms a long release profile of liraglutide, which was previously seen in rats.
2023-03-23	Nanexa AB	Results NEX-22 preclinical data shows controlled release of liraglutide for one month nanexa.com ↗ The results show a controlled release of liraglutide, with plasma exposure over 28 days for NEX-22, compared to around 2 days for a formulation with liraglutide without the PharmaShell coating.
2022-10-27	Hangzhou Sciwind Biosciences Co., Ltd.	Results Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity sciwindbio.com ↗ After 18 weeks of treatment, participants receiving 2.4 mg XW003 weekly achieved a mean body weight reduction from baseline of 11.1% (10.9 kg), compared to 7.9% (8.1 kg) for participants receiving 3.0 mg liraglutide daily injections (P
2022-06-05	Eli Lilly and Company	Results Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study lilly.com ↗ All results for Jardiance compared with GLP-1 receptor agonists, and with liraglutide (a GLP-1 receptor agonist) specifically, were consistent for people with and without cardiovascular disease.
2022-01-28	4Moving Biotech	Results First scientific paper of 4Moving Biotech in Scientific Reports 4movingbiotech.com ↗ In this paper, we demonstrate that Liraglutide, an agonist of the GLP-1 receptor, ameliorates OA-associated pain, and possesses anti-inflammatory and analgesic properties.
2021-12-13	4Moving Biotech	Results Discover the latest 4P004 results presented by Coralie Meurot, PhD student at 4P-Pharma during the 34th SFR Congress 4movingbiotech.com ↗ Liraglutide exerts potent anti-inflammatory and anti-catabolic activity in two cell types found in osteoarthritis: chondrocytes and macrophages
2018-11-22	Novo Nordisk A/S	Results Oral semaglutid giver større reduktioner i både langtidsblodsukker og vægt sammenlignet med Victoza® hos japanere med type 2-diabetes novonordisk.com ↗ Endvidere medførte 14 mg oral semaglutid en statistisk signifikant større reduktion i HbA1c, mod en reduktion på 1,4% med Victoza®.
2018-11-22	Novo Nordisk A/S	Results Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes novonordisk.com ↗ Furthermore, 14 mg oral semaglutide achieved a statistically significantly greater reduction in HbA1c compared to a reduction of 1.4% with Victoza®.
2018-06-24	Eli Lilly and Company	Results Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW lilly.com ↗ These real-world data show that people starting on once-weekly Trulicity are associated with a higher likelihood of adhering to their treatment regimen and having a lower A1C compared to two other GLP-1 RA options.
2018-06-20	Novo Nordisk A/S	Results Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenlignet med Victoza® og sitagliptin i PIONEER 4 og 7 novonordisk.com ↗ PIONEER 4 opfyldte sit primære mål vurderet ud fra den primære statistiske metode, idet det viste en ikke-inferiør reduktion i langtidsblodsukkeret (HbA1c) og et statistisk signifikant og større vægttab ved 26 uger med oral semaglutid sammenlignet med Victoza®.
2018-06-20	Novo Nordisk A/S	Results Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials novonordisk.com ↗ PIONEER 4 achieved its primary objective according to the primary statistical approach by demonstrating a non-inferior reduction in HbA1c and statistically significant and superior weight loss at 26 weeks with oral semaglutide compared to Victoza®.
2017-09-05	Adocia	Results Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes adocia.com ↗ The present poster demonstrates that the proprietary BioChaperone® technology enables solubilization of insulin glargine at neutral pH, which in turns allows its combination with multiple GLP -1 receptor agonists in solution.
2017-08-25	Novo Nordisk A/S	Regulatory Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events novonordisk.com ↗ The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.
2017-08-25	Novo Nordisk A/S	Regulatory Victoza® godkendt i USA som eneste behandling af type 2-diabetes med indikation til at nedsætte risikoen for alvorlige kardiovaskulære hændelser novonordisk.com ↗ De amerikanske sundhedsmyndigheder (FDA) har godkendt en ny indikation for Victoza® (liraglutid) til nedsættelse af risikoen for alvorlige kardiovaskulære (hjerte-kar-relaterede) hændelser hos voksne med type 2-diabetes og konstateret hjerte-kar-sygdom.
2017-07-27	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events novonordisk.com ↗ The European Commission has approved an update to the Victoza® (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment.
2017-07-27	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: Victoza® godkendt i EU som eneste GLP-1 med indlægsseddel, der omfatter forebyggelse af kardiovaskulære hændelser novonordisk.com ↗ Europa-Kommissionen har godkendt en opdatering af indlægssedlen for Victoza® (liraglutid) i EU, der udvider indikationen, så den afspejler både blodsukker- og kardiovaskulære hændelser som integreret del af behandlingen af type-2 diabetes.
2017-06-23	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial novonordisk.com ↗ Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU label for Victoza®.
2017-06-23	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Victoza® i EU baseret på LEADER-studiet novonordisk.com ↗ Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om opdatering af indlægssedlen for Victoza® i EU.
2017-06-23	Novo Nordisk A/S	Results Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial novonordisk.com ↗ The results from the liraglutide 3.0 mg treatment arm were broadly in line with previously reported data.
2017-06-22	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: CHMP støtter opdatering af indlægssedlen for Saxenda® i EU baseret på LEADER-studiet novonordisk.com ↗ Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) støtter en opdatering af indlægssedlen for Saxenda® i EU.
2017-06-22	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial novonordisk.com ↗ Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under theEuropean Medicines Agency (EMA), has endorsed an update of the EU label for Saxenda®.
2017-06-20	Novo Nordisk A/S	Regulatory Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes novonordisk.com ↗ The Advisory Committee voted 17-2 in favour of Victoza® on the question: "Does the LEADER trial provide the substantial evidence needed to establish that Victoza® (liraglutide 1.8 mg) reduces cardiovascular risk in patients with type 2 diabetes?"
2017-06-20	Novo Nordisk A/S	Regulatory Novo Nordisk får positiv 17-2 afstemning fra FDA's rådgivende komite om, at Victoza® giver væsentlig dokumentation for nedsættelse af kardiovaskulær risiko hos mennesker med type 2-diabetes novonordisk.com ↗ Den rådgivende komite stemte 17-2 til fordel for Victoza® i spørgsmålet: "Giver LEADER-studiet den væsentlige dokumentation, der er nødvendig for at fastslå, at Victoza® (liraglutid 1,8 mg) reducerer kardiovaskulær risiko hos patienter med type 2-diabetes?"
2017-02-02	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Confirms Generic Victoza® Patent Challenge in the United States tevapharm.com ↗ filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market the generic version of Novo Nordisk's Victoza® (liraglutide) injection, in the U.S.
2016-10-25	Novo Nordisk A/S	Regulatory Novo Nordisk indsender ansøgning til registreringsmyndighederne om inkludering af data fra LEADER-studiet i indlægssedlen for Victoza® novonordisk.com ↗
2016-10-25	Novo Nordisk A/S	Regulatory Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label novonordisk.com ↗
2016-09-02	Novo Nordisk A/S	Regulatory FDA forlænger registreringsprocessen for IDegLira med tre måneder novonordisk.com ↗ Novo Nordisk A/S meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har forlænget registreringsprocessen for IDegLira, et kombinationsprodukt bestående af insulin degludec og liraglutid i et fast kombinationsforhold til behandling af voksne med type 2-diabetes.
2016-03-04	Novo Nordisk A/S	Results Victoza® reducerer risikoen for alvorlige kardiovaskulære hændelser signifikant i LEADER-studiet novonordisk.com ↗ Studiet sammenlignede tilføjelsen af enten Victoza® eller placebo til standardbehandling og opfyldte det primære mål om at vise ikke-inferiøritet samt at dokumentere superioritet med en statistisk signifikant reduktion i kardiovaskulær risiko.
2016-03-04	Novo Nordisk A/S	Results Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial novonordisk.com ↗ The trial compared the addition of either Victoza® or placebo to standard of care and met the primary endpoint of showing non-inferiority as well as demonstrating superiority, with a statistically significant reduction in cardiovascular risk.
2015-08-24	Novo Nordisk A/S	Results Novo Nordisk afslutter andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin ved behandling af type 1-diabetes (NN9211) novonordisk.com ↗ Novo Nordisk offentliggør i dag de overordnede resultater fra det andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin til behandling af mennesker med type 1-diabetes.
2015-08-24	Novo Nordisk A/S	Results Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) novonordisk.com ↗ Novo Nordisk today announced headline results from the second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes.
2015-06-06	Eli Lilly and Company	Results Study: Once-Weekly Trulicity™ (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks lilly.com ↗
2015-03-23	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: Saxenda® godkendt i Europa til behandling af fedme novonordisk.com ↗ Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Saxenda® (liraglutid 3 mg) til behandling af fedme.
2015-03-23	Novo Nordisk A/S	Regulatory Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity novonordisk.com ↗ Novo Nordisk today announced that the European Commission has granted marketing authorisation for Saxenda® (liraglutide 3 mg) for the treatment of obesity.
2015-01-22	Novo Nordisk A/S	Regulatory Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity novonordisk.com ↗ Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity.
2015-01-22	Novo Nordisk A/S	Regulatory Novo Nordisk får positiv udtalelse fra de europæiske registreringsmyndigheder for Saxenda® (liraglutid 3 mg) til behandling af fedme novonordisk.com ↗ Bagsværd, den 22. januar 2015 - Novo Nordisk meddeler i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMA) har afgivet en positiv udtalelse om brug af Saxenda® (liraglutid 3 mg) til behandling af fedme.
2014-12-23	Novo Nordisk A/S	Regulatory Novo Nordisk får FDA-godkendelse for Saxenda® til behandling af fedme novonordisk.com ↗ Novo Nordisk meddeler i dag, at de amerikanske sundhedsmyndigheder (FDA) har godkendt registreringsansøgningen for Saxenda® (liraglutid 3 mg), den første humane GLP-1-analog (glukagonlignende peptid-1) til dosering én gang dagligt til behandling af fedme.
2014-12-23	Novo Nordisk A/S	Regulatory Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity novonordisk.com ↗ Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.
2014-09-11	Novo Nordisk A/S	Regulatory FDA's rådgivende komite anbefaler godkendelse af Saxenda® til behandling af fedme med stemmerne 14-1 novonordisk.com ↗
2014-09-11	Novo Nordisk A/S	Regulatory Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee novonordisk.com ↗
2014-06-14	Eli Lilly and Company	Results Lilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial lilly.com ↗ At the primary endpoint of 26 weeks, once-weekly dulaglutide 1.5 mg and once-daily liraglutide 1.8 mg significantly reduced HbA1c levels from baseline (-1.42 percent and -1.36 percent, respectively), with dulaglutide demonstrating non-inferiority compared to liraglutide.
2014-05-20	Novo Nordisk A/S	Regulatory FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity novonordisk.com ↗ Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 11 September 2014 to discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of obesity.
2014-02-25	Eli Lilly and Company	Results Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes lilly.com ↗ In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non-inferiority to once-daily liraglutide 1.8 mg, as measured by the reduction of hemoglobin A1c (HbA1c) from baseline at 26 weeks.
2013-12-20	Novo Nordisk A/S	Regulatory Novo Nordisk indsender registreringsansøgning for liraglutid 3 mg til behandling af fedme novonordisk.com ↗ Novo Nordisk har indsendt en NDA-ansøgning (New Drug Application) til de amerikanske sundhedsmyndigheder (FDA) og en MAA-ansøgning (Marketing Authorisation Application) til Det Europæiske Lægemiddelagentur (EMA).
2013-12-20	Novo Nordisk A/S	Regulatory Novo Nordisk files for regulatory approval of liraglutide 3 mg for the treatment of obesity novonordisk.com ↗ The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA).
2013-05-23	Novo Nordisk A/S	Results Novo Nordisk rapporterer 8% vægttab i fase 3a-fedmestudie med liraglutid 3 mg novonordisk.com ↗
2013-05-23	Novo Nordisk A/S	Results Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg novonordisk.com ↗
2013-03-18	Novo Nordisk A/S	Results Type 2-diabetikere opnår 6% vægttab med liraglutid 3 mg i fase 3a-fedmestudie novonordisk.com ↗ Novo Nordisk har i dag offentliggjort hovedresultaterne fra et 56-ugers dobbeltblindt klinisk studie i fase 3a, som har undersøgt liraglutids potentiale med hensyn til at fremkalde og opretholde vægttab hos overvægtige eller svært overvægtige mennesker med type 2-diabetes.
2013-03-18	Novo Nordisk A/S	Results People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial novonordisk.com ↗ Novo Nordisk today announced the headline results from a 56-week, double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in overweight or obese people with type 2 diabetes.
2012-06-09	GlaxoSmithKline	Results GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes gsk.com ↗
2012-04-06	Novo Nordisk A/S	Regulatory Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia® novonordisk.com ↗ Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin).
2012-04-06	Novo Nordisk A/S	Regulatory Indlægsseddel for Victoza® i USA opdateret med data, som viser, at Victoza® virker bedre end Januvia® novonordisk.com ↗ Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder (FDA) har godkendt, at indlægssedlen for Victoza® (liraglutid) opdateres med data, som viser at Victoza® giver bedre blodsukkerkontrol og vægtreduktion end Januvia® (sitagliptin).
2011-11-16	GlaxoSmithKline	Results GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes gsk.com ↗ Results showed a reduction in HbA1c of 0.78% for patients receiving albiglutide compared to a reduction of 0.99% for liraglutide.
2011-03-15	Novo Nordisk A/S	Regulatory Novo Nordisk opnår godkendelse af Victoza® i Kina novonordisk.com ↗ Novo Nordisk meddelte i dag, at de kinesiske sundhedsmyndigheder, State Food and Drug Administration (SFDA), har godkendt Victoza® til behandling af type 2-diabetes.
2011-03-15	Novo Nordisk A/S	Regulatory Novo Nordisk receives approval for Victoza® in China novonordisk.com ↗ Novo Nordisk announced today that the Chinese State Food and Drug Administration (SFDA) has approved Victoza® for the treatment of type 2 diabetes.
2011-03-03	Eli Lilly and Company	Results DURATION-6 Top-Line Study Results Announced lilly.com ↗ Results showed that patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza.
2011-03-03	Alkermes, Inc.	Results DURATION-6 Top-Line Study Results Announced alkermes.com ↗ Results showed that patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza.
2010-01-26	Novo Nordisk A/S	Regulatory Novo Nordisk modtager godkendelse for Victoza® (liraglutid) i USA til behandling af type 2-diabetes novonordisk.com ↗ Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har givet markedsføringstilladelse for Victoza® til behandling af type 2-diabetes hos voksne.
2010-01-26	Novo Nordisk A/S	Regulatory Novo Nordisk receives US approval for Victoza® (liraglutide) for the treatment of type 2 diabetes novonordisk.com ↗ Novo Nordisk announced today that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza® for the treatment of type 2 diabetes in adults.
2010-01-20	Novo Nordisk A/S	Regulatory Novo Nordisk får markedsføringstilladelse for Victoza® i Japan novonordisk.com ↗ Novo Nordisk meddelte i dag, at det japanske sundhedsministerium har godkendt Victoza® til behandling af type 2-diabetes.
2010-01-20	Novo Nordisk A/S	Regulatory Novo Nordisk receives approval for Victoza® in Japan novonordisk.com ↗ Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes.
2009-07-03	Novo Nordisk A/S	Regulatory Novo Nordisks Victoza® (liraglutid) får markedsføringstilladelse i Europa novonordisk.com ↗ Novo Nordisk meddeler i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Victoza® til behandling af voksne med type 2-diabetes.
2009-07-03	Novo Nordisk A/S	Regulatory Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe novonordisk.com ↗ Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza® for the treatment of type 2 diabetes in adults.
2009-04-23	Novo Nordisk A/S	Regulatory Novo Nordisk receives positive opinion on Victoza® (liraglutide) from the European regulatory authorities novonordisk.com ↗ Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMEA) adopted a positive opinion, recommending marketing authorisation, for Victoza® for treatment of type 2 diabetes.
2009-04-23	Novo Nordisk A/S	Regulatory Novo Nordisk modtager positiv udtalelse om Victoza® (liraglutide) fra de europæiske registreringsmyndigheder novonordisk.com ↗ Novo Nordisk meddelte i dag, at Udvalget for Humanmedicinske Lægemidler (CHMP) under Det Europæiske Lægemiddelagentur (EMEA) har vedtaget en positiv udtalelse om Victoza® til behandling af type 2-diabetes og dermed anbefaler at give produktet markedsføringstilladelse.
2008-11-18	Novo Nordisk A/S	Regulatory FDA meddeler ny dato for møde i rådgivende komite om liraglutide - samlet tidsplan forventes ikke ændret novonordisk.com ↗ De amerikanske sundhedsmyndigheder, FDA, har meddelt Novo Nordisk, at det planlagte møde om liraglutide i FDA's rådgivende komite den 2. marts 2009 er blevet rykket til den 2. eller 3. april 2009.
2008-11-18	Novo Nordisk A/S	Regulatory FDA reschedules Advisory Committee meeting for liraglutide - no change of review timeline anticipated novonordisk.com ↗ The US Food and Drug Administration (FDA) has informed Novo Nordisk that the planned Advisory Committee meeting for liraglutide on 2 March 2009 has been rescheduled to 2 or 3 April 2009.
2008-09-26	Novo Nordisk A/S	Results Novo Nordisk provides update on corporate strategy at its Capital Markets Day novonordisk.com ↗ New data from a 14-week extension of the LEAD(TM) 6 study confirms promising profile of liraglutide
2008-09-05	Novo Nordisk A/S	Regulatory FDA berammer møde i rådgivende komite om liraglutide novonordisk.com ↗ De amerikanske sundhedsmyndigheder, FDA, har meddelt Novo Nordisk, at der vil blive afholdt et møde i FDA's rådgivende komite den 2. marts 2009, hvor registreringsansøgningen for liraglutide - en human GLP-1-analog til dosering én gang dagligt - vil blive drøftet.
2008-09-05	Novo Nordisk A/S	Regulatory FDA schedules Advisory Committee meeting for liraglutide novonordisk.com ↗ Novo Nordisk today announced that the Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is scheduled to be held on 2 March 2009 to discuss the New Drug Application (NDA) for liraglutide, a once-daily human GLP-1 analogue.
2008-07-15	Novo Nordisk A/S	Regulatory Novo Nordisk indsender registreringsansøgning for liraglutide i Japan novonordisk.com ↗ Novo Nordisk har indsendt registreringsansøgning til de japanske myndigheder med henblik på godkendelse af den humane GLP-1-analog liraglutide til behandling af type 2-diabetes.
2008-07-15	Novo Nordisk A/S	Regulatory Novo Nordisk files for regulatory approval of liraglutide in Japan novonordisk.com ↗ Novo Nordisk today announced the submission of a new drug application to the Ministry of Health, Labour and Welfare in Japan for the approval of liraglutide, a once-daily human GLP-1 analogue, for the treatment of people with type 2 diabetes.
2008-06-16	Novo Nordisk A/S	Results Signifikant vægttab fastholdes hos svært overvægtige efter behandling med liraglutide i et år novonordisk.com ↗ Novo Nordisk har i dag offentliggjort kliniske resultater fra en 32-ugers åben forlængelse af et 20-ugers fedmestudie i fase 2, hvor behandling med liraglutide, den humane GLP-1-analog til dosering én gang dagligt, blev testet på svært overvægtige uden diabetes.
2008-06-16	Novo Nordisk A/S	Results Significant weight loss sustained in obese people treated with liraglutide for one year novonordisk.com ↗ After 52 weeks, liraglutide given once daily at the highest dose led to a mean weight loss from baseline of around 7.5-8.0 kg and a placebo-adjusted weight loss of around 5.5-6.0 kg, compared to a weight loss after 20 weeks of just above 7 kg from baseline and 4.5 kg placebo-adjusted.
2008-06-06	Novo Nordisk A/S	Results Klinisk studie viser, at liraglutide giver statistisk signifikant bedre blodsukkerregulering end exenatide novonordisk.com ↗ Patienter, der fik liraglutide, opnåede en reduktion i HbA1c på mere end 1,1 procentpoint, sammenlignet med en reduktion i HbA1c på mindre end 0,8 procentpoint i exenatide-gruppen - en statistisk signifikant forskel.
2008-06-06	Novo Nordisk A/S	Results Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide novonordisk.com ↗ Patients treated with liraglutide achieved a reduction in HbA1c of more than 1.1 percentage points, compared to a reduction in HbA1c of less than 0.8 percentage points in the exenatide group, a difference which was statistically significant.
2008-05-23	Novo Nordisk A/S	Regulatory Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe novonordisk.com ↗ Novo Nordisk today announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) in the US as well as a marketing authorisation application to the European Medicines Agency (EMEA) in Europe
2008-05-23	Novo Nordisk A/S	Regulatory Novo Nordisk indsender registreringsansøgning for liraglutide i USA og Europa novonordisk.com ↗ Novo Nordisk har i dag indsendt registreringsansøgning til de amerikanske sundhedsmyndigheder (FDA) og ansøgning om europæisk markedsføringstilladelse til Det Europæiske Lægemiddelagentur (EMEA) med henblik på godkendelse af den humane GLP-1-analog liraglutide til behandling af type 2-diabetes.
2007-12-11	Novo Nordisk A/S	Results Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight novonordisk.com ↗ At both doses tested, liraglutide provided statistically significantly better glucose control than glimepiride.
2007-12-11	Novo Nordisk A/S	Results Afsluttende fase 3-studie bekræfter, at liraglutide har en overbevisende effekt på blodsukkerregulering og vægt novonordisk.com ↗ Ved begge de afprøvede doser gav liraglutide en statistisk signifikant bedre blodsukkerregulering end glimepiride.
2007-11-20	Novo Nordisk A/S	Results Nyt fase 2-studie viser, at liraglutide medfører signifikant vægttab hos svært overvægtige novonordisk.com ↗ Alle doser af liraglutide medførte en vægtreduktion.
2007-11-20	Novo Nordisk A/S	Results New phase 2 study shows that liraglutide leads to significant weight loss in obese people novonordisk.com ↗ All doses of liraglutide reduced body weight.
2007-09-14	Novo Nordisk A/S	Results Fase 3-studie bekræfter, at behandling med liraglutide sænker både blodsukker og vægt med lav risiko for hypoglykæmi novonordisk.com ↗ Novo Nordisk offentliggør i dag kliniske resultater fra det fjerde af i alt fem fase 3-studier med liraglutide - den humane GLP-1-analog til dosering én gang dagligt.
2007-09-14	Novo Nordisk A/S	Results Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events novonordisk.com ↗ At the end of the study, more than 50% of the patients in the liraglutide-treated group had reached the American Diabetes Association goal of HbA1c < 7%.
2007-08-20	Novo Nordisk A/S	Results Liraglutide forbedrer blodsukkerregulering og medfører vægttab, viser to fase 3-studier med mere end 2.000 patienter novonordisk.com ↗ Novo Nordisk offentliggør i dag kliniske resultater fra det andet og tredje af i alt fem fase 3-studier med liraglutide - den humane GLP-1-analog til dosering én gang dagligt.
2007-08-20	Novo Nordisk A/S	Results Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients novonordisk.com ↗ In the LEAD® 1 study, liraglutide provided statistically significantly better glucose control than rosiglitazone.
2007-06-21	Novo Nordisk A/S	Results Liraglutide giver en væsentligt bedre blodsukkerregulering end insulin glargine i fase 3-studie novonordisk.com ↗ HbA1c-reduktionen i liraglutide-gruppen var mere end 0,2 procentpoint bedre end i insulin glargine-gruppen - en statistisk signifikant forskel.
2007-06-21	Novo Nordisk A/S	Results Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study novonordisk.com ↗ The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant.
2005-11-25	Novo Nordisk A/S	Results Promising clinical results from liraglutide phase 2b study novonordisk.com ↗ An improvement of haemoglobinA1c (HbA1c) of between 1.5 and 2 percentage points was achieved by treatment with liraglutide compared to placebo.
2005-11-25	Novo Nordisk A/S	Results Lovende kliniske resultater fra fase 2b-studiet med liraglutide novonordisk.com ↗ Novo Nordisk har i dag offentliggjort en række kliniske resultater fra fase 2b-studiet med liraglutide, en fuldt human GLP-1-analog til dosering én gang dagligt.

All press releases naming this drug 136 releases

Date	Issuer	Release
Show all 136 releases opens the full record — a long page

Evidence & citations 22 cited values

Every value below carries the sentence it was read from. 426 sources stand behind the page.

Field	Value	Cited text
Known as	Liraglutide	“Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required...” NCT03795701 ↗ 400 “The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA...” NCT06256419 ↗ “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗ “Subjects will be randomized 1:1 to open-label eucaloric very-low carbohydrate ketogenic diet (<40 g of carbohydrate) or standard of care (i.e. metformin, followed by...” NCT07866846 ↗ “The combination of insulin degludec (100 units/mL) and liraglutide (3.6 mg/mL), termed IDegLira, was approved in 2014 for the treatment of type 2 diabetes inadequately...” NCT04190160 ↗ “AIMS: β-cell stress and dysfunction may contribute to islet autoimmunity and progression to clinical type 1 diabetes. We present a protocol of three randomised controlled...” PMID 35797241 ↗ Jul 2022 “Liraglutide injection,developed and marketed as Victoza® by Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved by the U.S. Food and...” NCT04373967 ↗ “Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group.” NCT06374875 ↗ “Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists” NCT06449235 ↗ “In this study, patients received standard clinical doses (e.g., liraglutide 1.2-1.8 mg once daily or semaglutide 0.5-1.0 mg once weekly) for 6 months.” NCT07539584 ↗ “Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice.” NCT02577848 ↗ Show 390 more sources
Known as	- liraglutide (Victoza)	“- liraglutide (Victoza®)” NCT02244164 ↗ 1 “liraglutide (Victoza)” NCT07325435 ↗
Known as	CinnaGen-liraglutide	“CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously.” NCT03421119 ↗
Known as	LIRA	“The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum...” NCT01664247 ↗ 5 “AIM: Two treatment strategies were compared in patients with type 2 diabetes (T2DM) on basal insulin requiring intensification: addition of once-daily (OD) liraglutide (Lira)...” PMID 24443830 ↗ Feb 2014 “OBJECTIVE: To observe the effect of liraglutide (LIRA) in combination of umbilical cord mesenchymal stem cells (hUC-MSCs) in treating type 2 diabetes mellitus.” PMID 27143183 ↗ May 2016 “liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.” PMID 32220916 ↗ Mar 2020 “Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug.” NCT02909933 ↗ “using the GLP-1 analog liraglutide (LIRA) as a comparator in T2DM.” PMID 29545266 ↗ Mar 2018
Known as	LIRA 3 mg	“To study the efficacy and safety of the GLP-1 analog liraglutide 3 mg (LIRA 3 mg) vs. placebo (PL) for reduction of body weight (BW) and hyperandrogenism in women with...” PMID 35710599 ↗ Jun 2022
Known as	Liraglutida	ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗
Known as	Liraglutide (rdna origin)	ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗
Known as	Liraglutide (Vicotza)	“Liraglutide (Vicotza)” NCT01677104 ↗
Known as	Liraglutide component of xultophy 100/3.6	ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗
Known as	Liraglutide recombinant	ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗
Known as	liraglutide\_obesity	“Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide\_obesity) starting at 0.6 mg qd.” NCT06217848 ↗
Known as	Melitide	“The aim of this study was to compare the efficacy and safety of a biosimilar liraglutide (Melitide®; CinnaGen, Tehran, Iran) to the reference liraglutide (Victoza®; Novo...” PMID 37707701 ↗ Sep 2023
Known as	NN-9924	ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗
Known as	NN2211	“This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-acting GLP-1 derivative liraglutide (NN2211) on glycemic...” PMID 15277417 ↗ Aug 2004 3 “We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell...” PMID 15111485 ↗ May 2004 “after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.” PMID 15161785 ↗ Jun 2004 “Liraglutide (NN2211) is a long-acting GLP-1 analogue” PMID 16026367 ↗ Aug 2005
Known as	NNC 90-1170	“A Randomised, Double-blind Within Dose Group, Single-centre, Placebo-controlled, Parallel 2-different Dose Group, 14-day Multiple s.c. Doses Study to Assess the Safety,...” NCT01615978 ↗ 5 “A Randomised, Double-blind, Single-centre, Placebo-controlled, 21-day Multiple s.c. Doses, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and...” NCT01620476 ↗ “NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone” NCT01511172 ↗ “NNC 90-1170 (liraglutide)” NCT01620463 ↗ “NNC 90-1170 (liraglutide)” NCT01507272 ↗ NCT00013910 ↗
Known as	Saxenda	“Liraglutide, a glucagon-like peptide-1 analog, approved for the treatment of obesity at the dose of 3 mg per day and commercialized under the name of Saxenda, was proved to...” NCT03534310 ↗ 22 “Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of...” NCT05111912 ↗ “Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.” NCT06374875 ↗ “after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.” NCT03347890 ↗ “The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide).” NCT06865365 ↗ “Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])” NCT03799198 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT03520062 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT07590219 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT04186494 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT03279731 ↗ “liraglutide 3 mg (Saxenda®) once-daily” NCT04781998 ↗ Show 12 more sources
Known as	Victoza	“Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for...” NCT01451905 ↗ 31 “Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for...” NCT01460069 ↗ “This study aimed to evaluate the pharmacokinetics (PKs), safety, and immunogenicity of the biosimilar (RD12014) compared to reference liraglutide (Victoza) in healthy Chinese...” PMID 35871497 ↗ Jul 2022 “Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes” NCT02730377 ↗ “The study seeks to document the utility of a SL formulation of the approved active ingredient liraglutide, currently marketed in a subcutaneous (SC) formulation as Victoza®.” NCT05268237 ↗ “Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.” NCT06374875 ↗ “Liraglutide 1.8 mg (Victoza), starting with 2-week dose escalation, was administered subcutaneously once daily as an open-label reference arm.” PMID 28768173 ↗ Aug 2017 “liraglutide developed by Novo Nordisk (Victoza®) also has beneficial effects in type 2 diabetes mellitus as has been proven by several trials” NCT01638260 ↗ “To date, 2 publications have evaluated the safety profile and efficacy of an aGLP1, liraglutide (Victoza®), in diabetic dialysis patients.” NCT04529278 ↗ “Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion” NCT02231658 ↗ “Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus” NCT02014740 ↗ Show 21 more sources
Known as	Victoza (liraglutide)	“Victoza (liraglutide)” NCT03010683 ↗
Action	Activate	“The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide” PMID 22174428 ↗ Dec 2011
Modality	Peptide	“Liraglutide, a once-daily human glucagon-like peptide-1 analogue” PMID 18201212 ↗ Jan 2008
Route	Other	“Liraglutide or placebo is administered by injection once daily in the evening.” NCT00154401 ↗
Target	GLP1R	“OBJECTIVE: The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to...” PMID 18931095 ↗ Oct 2008